Diverticulitis Disease

Published Date : Aug 2023
Category : Infectious Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

The Service Architecture for Diverticulitis Disease

“Beginning the Diverticulitis Revolution: Stimulating Business Growth”

The thrilling journey into the field of diverticulitis therapy is explored by DiseaseLandscape Insights, where remarkable developments and paradigm-shifting opportunities are transforming the industry landscape.

Diverticulitis is a common gastrointestinal condition that is associated with high morbidity and high medical expenditures. Acute diverticulitis accounts for 3.8% of the reasons for stomach discomfort in patients seen in emergency departments. Diverticulitis affects 10%-25% of persons with known colonic diverticulosis during their lives. According to NCBI, diverticula infect any section of the colon, but in 95% of cases, the sigmoid colon is the only area affected.

Diverticulitis is becoming more common globally. Increased prevalence and incidence rate of the disease is changing the lifestyle of the individual. Improving the status and evolving the techniques for patient health provide new prospects and a clear vision for the market player to grow in this field.

Diverticula is present in more than 50% of adults over the age of 60 and more than 60% of people over the age of 80 in the US which may form inflammation. Diverticulitis causes more than 2.7 million outpatient visits and 200,000 hospitalizations per year in the US reported by NCBI. Furthermore, in the US and Europe, diverticulosis was most typically seen in the left and sigmoid colon (90%), whereas, in Asia, it was more commonly found in the ascending or right colon which accounts for (75-85%).

According to the World Gastroenterology Organization, the incidence of diverticulitis is 5% in people under the age of 40, whereas almost 30% in people under the age group of 60. Diverticulitis has become more common over time and increases with patient age. However, in recent years, the relative increase in diverticulitis has been greatest in young individuals.

Early identification of diverticulitis is demanding, although substantial advances in particular treatments and alternative therapies have been made. The global market study is based on increased sedentary lifestyle adaptability, large intake of alcohol, high smoking rate, and large gastrointestinal expansion. The major reason is also that the use of aspirin, steroids, and opioids are some of the risk factors for diverticulitis. The food item to be avoided in diverticulitis is red meat.

As stated by many organisations, a high-fibre diet, walking daily, maintaining weight and strong exercise have been demonstrated to reduce the incidence of complex diverticulitis by 25% as they are a natural cure for diverticulitis.

These changes and the adoption of launching new things have consistently been seen as a critical component in accelerating opportunities for market leaders on a global basis to expand their markets. As a result, these trends have contributed significantly to the proliferation of expanded things.

The DiseaseLandscape Insights services assist strategic choices across the Diagnostic, Treatment, and Medical Device Landscape

Diverticulitis Diagnostic Analysis

"Diverticulitis Diagnostic Advancement: Improving Patient Care"

Diverticulitis is normally diagnosed using a combination of medical history, physical examination, blood testing, and imaging studies. The common steps involved are:-

  1. Medical History and Physical Examination-

The initial phase of diagnosis involves checking the medical history of any patient as many people have a history of constipation or comparable pain episodes which helps in the identification of disease. In a physical examination, peritoneal irritation almost invariably results in discomfort to palpation across the area of inflammation. About 20% of individuals may feel a mass if an abscess is present.

In 24% to 68% of cases, medical history and physical examination-based diagnosis are inaccurate. Hence, blood tests and imaging tests play important role in accurate diagnosis.

  1. Blood Tests-

A full blood count, which should be done since leucocytosis is present in 55% of people with acute diverticulitis, is the most crucial diagnostic test that aids in the early detection of the disease. A urinalysis is useful to rule out a urinary tract infection. Tests for C-reactive protein are used to assess the severity and likelihood of recurrence of diverticulitis. In order to assess the severity and effects of disorders, stool tests are also carried out to screen for gastrointestinal bleeding.

  1. Imaging Tests Include -

An imaging test is the other important method to diagnose the disease and accurately helps in understanding the level of antigen count present in the body, following are the brief classifications of imaging tests.

  • Computational Tomography-

Images are created using a combination of X-rays and computer technology. Bowel wall thickening, tiny abscesses contained to the colonic wall, and signs of intramural sinus and fistula formation are common findings of acute diverticulitis in CT scans. More than 97% has been reported for the sensitivity, specificity, and negative prognosis of a CT scan. It also helps with categorizing the extent of the disease by detecting associated abscesses.

  • Ultrasound-

It projects an image of your internal organs using sound waves. Ultrasound has comparable sensitivity (84% to 94%) and specificity (80% to 93%) to CT in diagnosing diverticulitis.

  • Magnetic Resonance Imaging-

This type of imaging testing is used and preferred more over X-ray tests, instead of utilizing X-rays, MRI captures photos of the organs and soft tissues in your body. Colonic diverticulitis can be differentiated from primary colon cancer by using the Contrast‐enhanced MRI technique and non-contrast enhanced MRI used for differentiating sigmoid diverticulitis from sigmoid carcinoma with 100% sensitivity and specificity.

  1. Colonoscopy-

On imaging tests, there are overlapping characteristics between diverticulitis and colorectal cancer. Hence, colonoscopy is typically recommended to rule out colorectal cancer as approximately 10% of the time, CT findings alone are insufficient to rule out cancer stated by NIH.

The American Gastrointestinal Association recommends that a colonoscopy be conducted six to eight weeks after the remission of acute diverticulitis. Based on the Annals of internal medicine, colonoscopy is highly accurate for diagnosing diverticulitis, because of the high sensitivity (94%) and specificity (99%) of the CT instrument. Side effects of this test are the use of sedatives which may be harmful, there is the chance of bleeding from where abnormal tissue was removed and there may be a chance of perforation of the wall of the colon.

Diagnostic tests are often performed in laboratories, either public or private, that are outfitted with the necessary and occasionally expensive equipment as well as staff members who are trained and competent to carry out the tests. The global diverticulitis diagnostic market is highly competitive and owes large market players with a global presence.

The below table provides names of the market competitors who are transforming healthcare with their advanced diagnostic breakthroughs, are listed below,

Diagnostic Market Players

Blood Tests

Imaging Tests


Sun Pharmaceuticals Industries Ltd.

Med Imaging Solutions

GI View Ltd


Cipla Limited

DiagnoTech Corporation

FUJIFILM Holdings America Corporation

Thyrocare Technologies

Gastro Diagnostics.Ltd


Metropolis Healthcare Ltd.

UltraScan diagnostics

HUGER Medical Instrument Co., Ltd

Apollo Diagnostics

Radiance Imaging System

Pro Scope Systems


Max Healthcare

Hitachi Ltd.


Fortis Healthcare

Siemens Healthineers

Olympus America

Dr. Reddy’s Laboratory

Mindray Medical International Limited

Medtronic Plc


Dr. Lal Path labs

Esaote S.p.A.



SRL Diagnostics


PENTAX Medical


Diagnosis Products

Blood Tests Products

Imaging Products

Colonoscopy Product



PreXion 3D Excelsior CBCT Scanner

Welch Allyn’s Fiberoptic


Row CT Scanner

Rectum sigmoidoscopy Non-Sterile from Adlin


Flash CT Scanner

Welch Allyn’s Disposable

EMS Stat ™

CX CT Scanner


StatStrip Xpress®2






Diverticulitis Treatment Analysis

“Achieving Good Health: Analysing New Developments in Diverticulitis Treatment”

There are many treatment options for diverticular disease available in the market. By analysing the type of disease and other factors of individual patients the treatment is given to the patient. Depending on the disease's severity, a specific treatment plan is developed for diverticular disease. Treatments are listed below-

  1. IV medication
  2. Blood transfusion
  3. Surgery
  4. Laparoscopic lavage

 1. IV medication:

Individuals who require hospitalization should receive intravenous fluids and antimicrobials.

  • Antibiotics

    – According to the Clinical Practice Guidelines of the American Society of Colon and Rectal Surgeons, antibiotic therapy alone usually works well for abscesses smaller than 3 cm in case of acute complicated diverticulitis. However, it is recommended that antibiotics should be used specifically rather than frequently in patients with acute uncomplicated diverticulitis.

Rifaximin (XIFAXAN) an antibiotic is generally used to treat diverticulitis because it is specific for pathogenic intestinal microflora, does not harm the normal flora of the digestive system, and passes from stomach to intestine without being absorbed. Rifaximin is particularly efficient in the treatment of uncomplicated diverticulitis as well as in the treatment of moderate diverticulitis by showing antibiotic action.

2. Blood transfusion:

A blood transfusion may be required in an emergency if the patient has lost a significant amount of blood due to bleeding from a diverticulum.

According to NIH, diverticular bleeding affects less than 5% of people with diverticulosis and typically manifests as painless, sporadic, and substantial amounts of lower gastrointestinal bleeding.

Fortunately, 70 to 80% of diverticular hemorrhages recover naturally. A subsequent episode of bleeding will occur in 25 to 30% of these patients. But 20% of patients will require treatment measures such as blood transfusion to achieve hemostasis stated by NIH.

3. Surgery:

The best surgical method for each instance will be determined by considerations such as the level of inflammation in the area where the anastomosis is planned, the patient's stability and overall health, and any coexisting illnesses.

  • Elective surgery:

    In the presence of larger abscesses, they need to be treated by elective surgery. According to NIH incidence is more than doubled and prevalence is more than 10%. It is less beneficial than resection surgery because the recurrence rate is high that is 40%.
  • Resection surgery:

    Patients with diffuse peritonitis often need resection surgery with medical care.  It is not 100% curative and the rate of recurrent diverticulitis after resection surgery is 6–9%.

According to the DLI study, surgical intervention is required in 15% to 20% of patients having acute diverticulitis. A consequence of acute diverticulitis is fistula development. According to NCBI, there are less than 5% of people get fistulas; nevertheless, it has been identified in roughly 20% of patients who had diverticulitis surgery. Colo vesicular fistula is the most frequent type of fistula, which occurs in about 65% of cases and needs to be managed by surgery.

4. Laparoscopic lavage-

It is intraoperative irrigation of the peritoneal cavity with saline solution and reduces morbidity by 38%, reduces mortality, no complications, and hence it is beneficial over resection surgery stated by NIH.

Lack of clinical improvement, worsening sepsis, the onset of peritonitis, and the need for re-intervention are signs that laparoscopic lavage has failed.

To overcome failures in treatment area and achieve the new business heights, DiseaseLandscape will help market players to alter the treatment industry landscape.

DLI equips market players to keep one step ahead of the competition with our thorough analysis of treatment options, service contributions, inventory of products, and market competition. As a devoted partner to the pharmaceutical sector, we offer extensive support in arranging, carrying out, and evaluating clinical studies for the development of novel new drugs.

The global Diverticular treatment market is highly competitive and owes a large market player with a global presence. The below table shows the market leaders who are reshaping the landscape and driving innovation in the pursuit of improved health outcomes.

Treatment Market Players

IV Medication (Antibiotics)

Blood Transfusion





Terumo Corporation

Mayo Clinic

Merck & Co

Ecomed Solutions, LLC.


Cedars Sinai medical center

Johnson & Johnson

Kawasumi Laboratories, Inc.

UCLA medical center

Cubist Pharmaceuticals


Becton Dickinson and Company

B. Braun Melsungen AG

Cleveland clinic


Abbott Laboratories


Immucor Inc.


LYU Langone hospitals


Eli Lilly & Co


Becton Dickinson and Company

Keck medical center for USC



B. Braun Melsungen AG


Northwestern Memorial Hospital



Terumo Corporation


Houston methodist hospital



Grifols SA

Mayo clinic- phoenix



Kaneka Corporation

Johns Hopkins Hospital



Fresenius Kabi AG


Sun Pharmaceutical Industries

Haemonetics Corporation




Treatment Products


Blood Transfusion Products


Cellometer Auto 2000

Orpic™ (Ciprofloxacin)

Cellometer spectrum image cytometry system

Sulbacin™ (Ampicillin and Sulbactam)

Cellometer k2

Dalacin C™ (Clindamycin)

Cellometer X2

Flagyl™ (Metronidazole)

Celigo Imaging Cytometer

Nicpime AM™(Amikacin)

Cellaca MX

Bactrim™ (Sulfamethoxazole and trimethoprim)



Services Provided by DiseaseLandscape Insights in the continuously Expanding Diverticulitis Disease Market

"Data-Driven Strategies to Promote Your Business's Expansion"

DiseaseLandscape Insights provides overall information about the healthcare components as well as a market framework for Diverticulitis. DLI services provide the market analysis of research and developments in the drug discovery phase, risk evaluation of new drugs, and product launch expansion along with long-term planning for the key players in the disease dynamics.

DLI also serves in the data management of clinical and drug safety, and other medication-related documents as well as documents related to regulatory bodies. DLI provides the knowledge of different journal articles, abstracts for publications, from instructional marketing materials, and also from the websites of various medical organizations to various stakeholders.

Understanding the services of DiseaseLandscape Insights helps the market player including healthcare providers, researchers, and organizations to evaluate the existing management, and identify the gaps for improvement and development of strategies in the market.

Diverticulitis is a condition with a commercial side that focuses on a variety of services and products that strive to address the impacts of the disease, from management and prevention to additional therapy and research.

Regulatory Framework for Diverticulitis

“Regulatory Program: Ensuring A Better Working Environment”

The Disease Landscape Insights considers the regulatory ecosystem of different countries for diverticulitis disease. DLI provides data about risk assessment laws, import/export legislation, and surveillance to the key player. By choosing DLI services market players will definitely prevent and respond to Diverticulitis outbreaks for the safety and well-being of the impacted population.

However, according to the National Institutes of Health regulatory guidelines, a high intake of dietary fiber contributes to the prevention of diverticulitis. The Dietary Guidelines for Americans 2015-2020 recommend eating 100% whole grains, which are non-refined grains, for the prevention of diverticulitis.

In addition to above, there are well-informed recommendations from the American Society of Colon and Rectal Surgeons for the prevention of diverticulitis, which state that surgeons should recommend elective segmental resection on an individual basis rather than based on a set number of episodes and new evidence suggests that there is no benefit of antibiotics in immunocompetent patients with mild acute uncomplicated diverticulitis, in other cases antibiotics should be selective rather than that.

All in all, regulatory policies are impacting the diverticulitis industry significantly and DLI provides detailed analysis of different regional guidelines that are currently in place and potential futuristic change in diverticulitis disease industry.

Competitive Analysis

"Providing Establishments with A Competitive Edge in the Diverticulitis Market”

In order to strengthen their competitive position, a number of international players in the diverticulitis market are focusing on creating new products and enhancing the use of technology to improve existing approaches. Companies are also working on expansion strategies to expand their product offerings. These initiatives mostly involve regulatory approval for medicine research, acquiring partnerships, and concurrently focusing on collaboration.

For instance, rivals like GI View are creating a brand-new single-use endoscope called the AER-O-SCOP Colonoscope to meet the rising demand for single-use endoscopes to reduce the spread of diverticulitis, lower surgical costs, and comply with changing endoscopic hygiene recommendations.

Launching of this product into the diverticulitis industry has increased awareness of the product, new business relationships and the overall revenue for the company as well as GI view set the benchmark for other competitors to develop the new diagnostic techniques for Diverticulitis.

Furthermore, Pfizer is helping the government of Ghana to set up a medical drone delivery system in collaboration with Zipline and others to access the essential health products. Zipline's drones are now delivering about 150 essential products, including blood, vaccines, and required medications. Antibiotics like Rifaximin are now also delivered into the Diverticulitis patient by using Zipline drones. This innovation has established a standard for other stakeholders.

DiseaseLandscape Insights helps the industry player by providing intense knowledge about all the existing market players, their innovations, strategies, collaborations and helps for selecting correct marketplace to grow exponentially.

Market trends

"Market Decoding for Better Business Decisions."

The market is expanding because of the development of new technologies and the use of imaging tests for the diagnosis of diverticulitis.

“Human microbiome project” is involved in understanding the GI microflora and their relationships, which helps in the development of probiotics which held the largest market share in 2021. There are many market players operating in human microbiome projects. These industries help with the development of probiotic products and expand the market for market players.

With that Yakult Central Institute has recently Joint research with the Tokyo Metropolitan Institute of Gerontology for the establishment of regular consumption of dairy products containing the Lacticaseibacillus paracasei strain Shirota helps to stabilize the flora in the elderly's intestinal tract. Production of dairy products with specific strains of microbe is a growing market and creates the chances of manufacturing goods for the patient's health.

Additionally, there have been recent improvements in the production of whole grains to meet all nutritional needs, which presents major prospects to companies in the agri and biotech markets. 2021–2022 will see the production of 316.06 million tonnes of whole grains, according to the Ministry of Agriculture and Farmers Welfare.

Another factor in the market's expansion is the usage of antibiotics that are not absorbed for the treatment of diverticulitis. Rifaximin is one of the non-absorbable antibiotics. Diverticulitis is just one of the gastrointestinal illnesses it has been licenced to treat in more than 30 countries, which will drive the market worldwide.

Clinical Data Assessment:  

The increasing emphasis on comparative effectiveness research by the government emphasizes the importance of clinical trials in the practice of evidence-based medicine and health care reform. Clinical data helps the market players to properly compare medical therapy and achieve one of the primaries aims of health care reform. The study titles of the currently active clinical trials, as well as the phases in which they are being conducted, are included in the table below.


Phase 1

Phase 2

Phase 3

Phase 4


Combination of Curcumin and Berberine Therapy in the Treatment of Post Acute Diverticulitis (AD) Symptomatic Uncomplicated Diverticular Disease (SUDD)




In DiseaseLandscape Insights, the fascinating adventure into the world of diverticulitis treatment begins, where innovative advancements and remarkable revolutionary potential will revolutionize the disease landscape. The support of DiseaseLandscape makes it easier to establish and carry out clinical trials for novel therapies and pharmaceuticals, patient recruitment techniques, regulatory compliance, assuring positive trial outcomes, and so on.


In order to prevent and manage diverticulitis outbreaks, farmers receive assistance from DiseaseLandscape Insights in developing and putting into practise efficient therapies. Furthermore, there is a rising demand for diagnostic tools, clinical evaluations, and diverticulitis surgery as a result of raised awareness and predicted outbreaks.

Disease Landscape Insights will provide the necessary information and insight to key players who are involved in the manufacturing of treatment products. The assistance offered at DiseaseLandscape Insights makes it simpler to establish and carry out clinical trials for novel therapies and pharmaceuticals, patient recruitment strategies, and regulatory compliance for the market players.

This allows enterprises to do concentrated R&D, learn about contract manufacturing organizations, discover raw material suppliers, and assure legal compliance for the business. Disease Landscape Insights (DLI) assists all market participants in gaining a stronger foothold in the diverticulitis disease sector.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape